Delving into the ideal moment for post-pancreatic adenocarcinoma surgery chemotherapy, a simulated trial tracked 1491 patients. Noteworthy findings revealed a median survival of 29.9 months for late initiators (>4-8 weeks) versus 30.4 months for early starters (0-4 weeks). Encouragingly, delaying treatment up to 8 weeks post-surgery showed comparable safety, offering a nuanced approach that respects recovery timelines and enhances adjuvant therapy accessibility.
Journal Article by Kirkegård J, Ladekarl M, Lund A and Mortensen F in Ann Surg Oncol
© 2023. The Author(s).